Ingenium INGENOtyping(tm) Agreement with Bayer HealthCare AG Meets Milestone for Genetic Model Production

27-Jul-2004

Munich. Ingenium Pharmaceuticals AG announced today milestone achievement in the company's INGENOtyping(tm) agreement under which Ingenium develops specific genetic mouse models for Bayer HealthCare AG. The agreement stipulated the development of mouse models for Bayer target genes, a milestone that Ingenium reached with the recent delivery of the first required genetic model. No financial terms or further details of the ongoing agreement have been disclosed.

"The ability to access high-value genetic models is critical to overall pharmaceutical development success. INGENOtyping(tm) can provide a significant benefit to the process and we are pleased to demonstrate this to Bayer," said Michael C. Nehls, M.D., Ph.D., CEO of Ingenium. "Ingenium looks forward to an ongoing fruitful collaboration with Bayer."

Ingenium's INGENOtypingTM technology is a high-speed tool for the in vivo validation of drug targets. INGENOtypingTM produces in as little as four months murine models that carry unique genetic alterations in any target gene of interest. These models include knockouts as well as more subtle functional alterations, such as increased and reduced gene target activity. The technology has also been successfully applied to create genetic rat models, rapidly and on an industrial scale. The INGENOtypingTM technology is based on a genetically subtle chemical process that generates point mutations in genes and Ingenium's expertise in quickly and reliably producing rodent genetic models.

https://www.bionity.com/en/news/38787/ingenium-ingenotyping-tm-agreement-with-bayer-healthcare-ag-meets-milestone-for-genetic-model-production.html